English
Neuropathic pain refers to pains that arise as direct consequence of a lesion or disease affecting the somatosensory nervous system. It affects 5-10 % of the general population and represents heavy burden costs for the health insurance systems and the society. Clinically, neuropathic pains are characterized by aberrant symptoms of spontaneous or evoked pain such as hyperalgesia (lowering of pain threshold and increased pain evoked by a noxious stimulus) and allodynia (evocation of pain by a non-painful stimulus). Due to neuropathic pain severity and chronicity, patients often present comorbidities, such as cognitive symptoms. The management of neuropathic pain and comorbidities is still unsatisfactory. Currently available treatments, such as antidepressants (tricyclics and serotonin-noradrenaline reuptake inhibitors (SNRIs)) and anticonvulsants (pregabalin/gabapentin) show a limited efficacy to alleviate both painful and co-morbid symptoms, in spite of recent efforts made to stratify patients according to their sensory profile. The main objective of the present proposal is to propose a new therapeutic strategy based on targeting spinal serotonin 5-HT6 receptor-operated mTOR signalling to improve the management of neuropathic pains and cognitive comorbidities. To achieve that goal, the SERO6Pain project will explore whether mTOR signalling is enhanced in well-characterized preclinical models of neuropathic pain of different aetiologies (i.e. traumatic, toxic and metabolic) in rats, and characterize the underlying mechanisms using a combination of cell biology, pharmacological and behavioural approaches. In line with our preliminary data suggesting a role of serotonin 5-HT6 receptors in this non-physiological mTOR activation, we will explore whether allodynia and cognitive comorbidities are alleviated by inhibiting spinal 5-HT6-receptor-operated signalling in these models using complementary pharmacological, genetic and peptidyl mimetic strategies: i) Treating neuropathic animals with 5-HT6 receptor antagonists or inverse agonists or with pharmacological mTOR inhibitors ii) Silencing spinal 5-HT6 receptor or mTOR expression using shRNAs delivered intrathecally with lentiviruses iii) Disrupting physical interaction between spinal 5-HT6 receptor and mTOR (prerequisite to 5-HT6 receptor-operated mTOR activation) using an interfering peptide mimicking the mTOR binding site in the receptor C-terminal domain. The ultimate objective of the SERO6Pain project is to provide the proof of concept that blocking 5-HT6 receptor-operated mTOR signalling can improve management of neuropathic pains irrespective of their aetiology. It might lead to a repositioning of 5 HT6 receptor antagonists that are generally well-tolerated and are currently in phases I, II and III of clinical trials for the treatment of cognitive deficits of dementia such as Alzheimer’s disease and psychiatric disorders. It will also promote the development of new 5-HT6 receptor ligands with optimized pharmacological properties (inverse agonists vs. neutral antagonists, higher affinity and improved specificity), compared with existing molecules, thanks to the collaboration of the consortium with a chemist group of the University of Krakow, which has a great expertise in the design and synthesis of 5-HT6 receptor ligands. A repositioning of mTOR inhibitors, already prescribed to prevent graft rejection or for the treatment of various cancers, might also be envisaged, even though these compounds induce more important side-effects than 5-HT6 receptor ligands. Finally, if it is established that 5-HT6 receptor/mTOR interaction is “druggable” thanks its disruption with a peptidyl mimetic approach, this strategy might likewise be envisaged providing that small molecules targeting this interaction are developed instead of peptides.
